Hepion pharmaceuticals to participate in upcoming january virtual investor conferences

Edison, nj / accesswire / january 5, 2021 / hepion pharmaceuticals, inc. (nasdaq:hepa)("hepion"), a clinical stage biopharmaceutical company focused on artificial intelligence ("ai")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("nash") and liver disease, announced today that management will participate in two virtual investor conferences in january. h.c. wainwright bioconnect 2021 conference (january 11-14, 2021): hepion's pre-recorded presentation will be available for approximately 90 days on its website at www.hepionpharma.com under "events" in the investors section, beginning on monday, january 11, 2021.
HEPA Ratings Summary
HEPA Quant Ranking